Ironwood Pharmaceuticals (IRWD) Scheduled to Post Quarterly Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) will be releasing its earnings data before the market opens on Thursday, May 9th. Analysts expect Ironwood Pharmaceuticals to post earnings of $0.19 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Ironwood Pharmaceuticals Trading Up 0.1 %

NASDAQ:IRWD opened at $8.12 on Wednesday. Ironwood Pharmaceuticals has a twelve month low of $7.53 and a twelve month high of $15.70. The company has a market cap of $1.27 billion, a PE ratio of -1.25 and a beta of 0.57. The company’s 50 day moving average is $8.54 and its two-hundred day moving average is $10.60.

Insider Transactions at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 47,380 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $15.24, for a total transaction of $722,071.20. Following the sale, the insider now directly owns 224,796 shares of the company’s stock, valued at $3,425,891.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Jon R. Duane purchased 6,920 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average cost of $8.70 per share, with a total value of $60,204.00. Following the completion of the acquisition, the director now owns 121,028 shares of the company’s stock, valued at approximately $1,052,943.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Minardo John sold 47,380 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $722,071.20. Following the sale, the insider now owns 224,796 shares in the company, valued at approximately $3,425,891.04. The disclosure for this sale can be found here. Insiders have sold 273,008 shares of company stock worth $4,160,642 over the last quarter. 13.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Craig Hallum started coverage on shares of Ironwood Pharmaceuticals in a research note on Wednesday, January 17th. They set a “buy” rating and a $21.00 price objective for the company. StockNews.com downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. Wells Fargo & Company reduced their price objective on Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, March 1st. Finally, Piper Sandler upped their target price on Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.80.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.